-
A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio
Monday, April 27, 2020 - 2:14pm | 1248Read More...Among the six coronavirus vaccine candidates that have entered human trials, two belong to publicly listed U.S. companies: Moderna Inc (NASDAQ: MRNA) and Inovio Pharmaceuticals Inc (NASDAQ: INO). Both stocks have rallied in reaction to updates on R&D and funding. Moderna is up...
-
Analysts Unfazed By FDA Snub Of Sarepta's DMD Drug, Pin Hopes On Gene Therapy
Tuesday, August 20, 2019 - 12:59pm | 707Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT)'s new drug application for its second Duchenne muscular dystrophy drug received a a complete response letter from the FDA on Monday. The Analysts Nomura Instinet analyst Christopher Marai maintained a Buy rating on Sarepta with a $230 price...
-
After Biogen's Alzheimer's Update, Wall Street Reacts
Friday, July 6, 2018 - 1:27pm | 643Read More...Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news. The Analysts Raymond James' Laura Chico maintained a Market...
-
Inside Sarepta's Beat And Raise Q2
Thursday, July 20, 2017 - 9:51am | 295Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped up over 17 percent during Wednesday’s after-hours trading sessions, after the medical research and drug development company crushed earnings estimates. A Closer Look At Q2 Earnings Revenue: $35 million (consensus estimate was $22.3...
-
Why NICE Recommendation Is Turning Point For PTC Therapeutics Shares
Monday, April 18, 2016 - 1:30pm | 414Read More...Oppenheimer said the recent recommendation from NICE for Translarna is a "turning point" for PTC Therapeutics, Inc. (NASDAQ: PTCT) shares, as it bodes well for the upcoming CHMP review. The Importance Of Translarna To PTC On Friday, shares of PTC Therapeutics surged more than 40 percent after it...
-
Oppenheimer: Raptor Pharma Sale A 'Good Idea'
Thursday, April 7, 2016 - 10:54am | 234Read More...Trading in shares of Raptor Pharmaceutical Corp. (NASDAQ: RPTP) was halted owing to volatility following reports of the company evaluating a possible sale and looking to hire an investment bank for the same. Oppenheimer’s Christopher Marai maintained a Perform rating for the company,...
-
PTC Therapeutics: Oppenheimer Bull Cuts Target From $111 To $39; Jefferies Less Certain on Translarna
Tuesday, March 1, 2016 - 10:21am | 333Read More...Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) were down as much as 2 percent in the pre-market hours Tuesday following the U.S. FDA questioning the effectiveness of Translarna in nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC was notified that negative results from both Phase-2b and...
-
What You May Be Missing About PTC Therapeutics In Germany
Monday, February 29, 2016 - 10:05am | 357Read More...Oppenheimer’s Christopher Marai maintained an Outperform rating for PTC Therapeutics, Inc. (NASDAQ: PTCT) after the company announced that the German Federal Association of the Statutory Health Insurances [GKV-SV] had given an “unacceptable” decision in the arbitration related...
-
Oppenheimer Sees 'Significant Upside Potential' In PTC Therapeutics
Thursday, February 25, 2016 - 11:47am | 257Read More...Oppenheimer’s Christopher Marai maintained an Outperform rating for PTC Therapeutics, Inc. (NASDAQ: PTCT), while reducing the price target from $135 to $111. PTC Therapeutics is a biotechnology company focused on the development of Translarna, an orally delivered treatment for rare...
-
How Five Prime's Bristol-Myers Partnership Helps Investors
Monday, October 19, 2015 - 3:35pm | 356Read More...Five Prime Therapeutics Inc (NASDAQ: FPRX) shares have been volatile in 2015 and are up 104 percent since October 12. Oppenheimer’s Christopher Marai maintained an Outperform rating on the company, while raising the price target from $45 to $48. The company’s partnership with Bristol-...
-
35 Stock Ideas Oppenheimer Analysts Love Right Now
Saturday, October 17, 2015 - 10:11pm | 1463Read More...Oppenheimer just released its 35 top stock ideas for October and November. Here’s a rundown of the full list with analyst commentary included. 1. Turtle Beach Corp (NASDAQ: HEAR) Analyst Sean McGowan sees two drivers of the stock: the “resurgence in video games” and the rollout of...
-
Oppenheimer Sees Translarna Approval 'Likely,' Believes PTC Is 'Catalyst Rich' Through 1H'16
Friday, October 16, 2015 - 9:03am | 322Read More...PTC Therapeutics, Inc. (NASDAQ: PTCT) shares have declined 52.87 percent over the last six months, touching a low of $25.11 on September 29. Oppenheimer’s Christopher Marai has reiterated an Outperform rating on the company, while lowering the price target from $155 to $135. Marai...
-
PTC Therapeutics Could Quintuple In Price, Oppenheimer Predicts
Monday, October 5, 2015 - 3:02pm | 335Read More...Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) lost nearly 8 percent by Monday afternoon. The company released Phase 2 data at the International Congress of the World Muscle Society. Christopher Marai of Oppenheimer maintained an Outperform rating and unchanged $155 price target...
-
Oppenheimer Is Buying Alexion Pharma On Weakness
Thursday, September 24, 2015 - 10:56am | 272Read More...Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has seen a 15.53 percent decline in its share price in the past three months. Oppenheimer’s Christopher Marai has maintained an Outperform rating and price target of $228 on the company. Marai believes that the weakness in the stock...
-
Analysts See More Upside For Sarepta Therapeutics
Wednesday, May 20, 2015 - 4:48pm | 266Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) gained more than 60 percent Wednesday on news that it expects to complete an approval application for its lead drug candidate by mid-2015. The company's shares closed at $26.44, up $10.06. Sarepta is likely to go "significantly higher over...
